United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 139.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,387 shares of the biotechnology company's stock after buying an additional 13,041 shares during the period. Tudor Investment Corp ET AL owned about 0.05% of United Therapeutics worth $7,899,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. World Investment Advisors LLC acquired a new position in United Therapeutics in the 3rd quarter valued at $393,000. Tidal Investments LLC raised its position in shares of United Therapeutics by 33.1% in the third quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company's stock valued at $4,039,000 after buying an additional 2,803 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in United Therapeutics during the third quarter worth about $7,686,000. Franklin Resources Inc. grew its stake in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after acquiring an additional 123,929 shares in the last quarter. Finally, Oddo BHF Asset Management Sas purchased a new stake in United Therapeutics during the 3rd quarter valued at about $1,698,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $300.93, for a total value of $3,310,230.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,068,506.33. This trade represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,500 shares of company stock worth $27,782,280 over the last three months. Company insiders own 11.90% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on UTHR. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a report on Monday, April 21st. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $392.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded up $0.75 during mid-day trading on Friday, reaching $294.60. 583,692 shares of the company were exchanged, compared to its average volume of 443,058. The firm has a market cap of $13.28 billion, a price-to-earnings ratio of 12.94, a P/E/G ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a 1 year low of $256.08 and a 1 year high of $417.82. The firm's 50-day simple moving average is $301.96 and its 200 day simple moving average is $344.33.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same period in the previous year, the firm posted $6.17 earnings per share. The company's revenue was up 17.2% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.